What Eyconis does

Eyconis is a privately held, pre-clinical stage biopharmaceutical company founded in 2023 as a spinout of Ascendis Pharma (NASDAQ: ASND) and headquartered at 1200 Bridge Parkway, Suite 200, Redwood City, California. The company holds an exclusive, worldwide license to Ascendis's TransCon technology platform for ophthalmology applications, and is using that platform to develop long-acting therapeutics for the major causes of blindness, with an initial lead candidate targeting wet age-related macular degeneration (AMD) and additional programs directed at diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA).

The core technology — TransCon — combines known biology with prodrug and sustained-release technologies to produce a desired pharmacokinetic profile with predictable release of unmodified parent drug, supporting dosing intervals of six months or more. By localizing TransCon to ophthalmology, Eyconis is positioning to deliver clinically validated anti-VEGF and emerging medicines at substantially reduced injection frequency compared with the current standard of care (e.g., EYLEA, Lucentis, Vabysmo), which it intends to improve upon rather than displace at the molecular level.

Eyconis is pre-commercial and generates no product revenue today; future revenue, upon regulatory approval, is expected to come from sale of approved ophthalmology pharmaceuticals through traditional specialty pharmacy and physician-channel distribution. The company launched in 2023 with a $150 million external investor commitment from Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital, with Ascendis Pharma retaining equity and milestone ("biobucks") participation. In February 2024 Eyconis closed an additional ~$60.25 million tranche, and in October 2025 it filed a Form D exempt offering valued at approximately $89.75 million (~ $25 million already sold), reflecting continued capital deployment into IND-enabling activities and pipeline expansion. The senior leadership includes veterans of the EYLEA/EYLEA HD program at Regeneron (Vitti, Chu, Drosman) and the Lucentis/Vabysmo programs at Genentech/Roche (Stauch), signaling a deliberate capability bet on long-acting delivery within established anti-VEGF biology.

Name

Eyconis

Legal name

Eyconis, Inc.

Website

https://eyconis.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Eyconis is a pre-clinical stage biopharmaceutical company developing long-acting ophthalmology therapeutics using the TransCon prodrug/sustained-release technology platform licensed exclusively from Ascendis Pharma, targeting wet AMD, DME, RVO, and geographic atrophy.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmology therapeutics
• Retinal disease treatments
• Sustained-release drug delivery
• Ophthalmic biopharmaceuticals
• TransCon prodrug platform

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Revenue: Pre-commercial stage company. Eyconis is developing novel therapeutics for eye diseases (wet AMD, DME, RVO, GA) using TransCon technology. Revenue will be generated through sale of approved pharmaceutical products for ophthalmology upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Eyconis is a pre-clinical stage biopharmaceutical company developing a pipeline of novel, long-acting ophthalmology therapeutics based on the TransCon technology platform licensed exclusively worldwide from Ascendis Pharma. Its lead drug candidate targets wet age-related macular degeneration (AMD), with additional preclinical programs for diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA), all designed to achieve dosing intervals of six months or more.

Product overview

Eyconis is a pre-clinical stage biopharmaceutical company developing a pipeline of novel, best-in-class therapeutics for eye diseases using the TransCon technology platform licensed exclusively from Ascendis Pharma. The company's lead drug candidate targets wet age-related macular degeneration (AMD), with additional programs in development for diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA). The TransCon platform enables long-acting delivery of clinically validated and emerging medicines, potentially achieving six-month dosing intervals.

Differentiator

Problem solved

Functional benefit

Products and services

• TransCon Technology Platform for Ophthalmology A clinically validated drug development platform combining known biology with prodrug and sustained-release technologies to enable long-acting delivery of ophthalmology therapeutics, supporting dosing frequency of six months or more. Licensed exclusively worldwide from Ascendis Pharma for ophthalmology applications and used by Eyconis to develop its pipeline of treatments for major causes of blindness.
• Lead TransCon Ophthalmology Drug Candidate (Wet AMD Program)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Ascendis Pharma A/ScoreStrategic or Co-development Partner · 1 January 2023Ascendis Pharma granted Eyconis exclusive, worldwide license to develop, manufacture, and commercialize ophthalmology therapeutics using its clinically validated TransCon technology platform. Eyconis is a spinout of Ascendis Pharma, founded in 2023. Ascendis CEO Jan Møller Mikkelsen serves on Eyconis' Board of Directors.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• REGENXBIO: REGENXBIO is developing RGX-314 (in collaboration with AbbVie) for wet AMD and diabetic retinopathy using subretinal/suprachoroidal AAV gene therapy to provide sustained anti-VEGF expression. It is a key emerging competitor in long-acting wet AMD delivery.
• Kodiak Sciences: Kodiak Sciences is a clinical-stage ophthalmology biotech developing long-acting retinal therapies (tarcocimab and next-generation antibodies) targeting wet AMD, DME, and RVO. It is one of the closest publicly traded comparables in long-acting retinal biologics.
• Adverum Biotechnologies: Adverum is a clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD, positioning long-duration delivery against frequent anti-VEGF injections. It is a directly comparable emerging modality in the same retinal indications.

Emerging players

• Outlook Therapeutics: Outlook Therapeutics is a pre-commercial ophthalmology company developing ONS-5010/LYTENAVA (bevacizumab-vikg), an ophthalmic formulation for wet AMD. It is a comparable pre-revenue ophthalmology biotech pursuing retina indications.
• 4D Molecular Therapeutics: 4DMT is a clinical-stage genetic medicines company developing 4D-150 for wet AMD using intravitreal AAV gene therapy. It is an emerging long-acting delivery competitor in the same retinal indication space.
• Clearside Biomedical: Clearside Biomedical develops suprachoroidal delivery technology for retinal therapeutics (XIPERE approved for macular edema associated with uveitis). Its suprachoroidal platform is a comparable long-acting ocular delivery approach addressing similar retina specialist customers.
• Annexon, Inc. Annexon is a clinical-stage biotech developing tanruprubart for geographic atrophy, targeting complement C1q to address GA. It is an emerging player with meaningful overlap in Eyconis's GA program target indication.

Broad incumbents

• Apellis Pharmaceuticals: Apellis markets SYFOVRE (pegcetacoplan) for geographic atrophy, one of Eyconis's named target indications. As a recently launched ophthalmology biotech with an approved complement-based retinal drug, Apellis is a relevant late-stage comparator in GA.
• Regeneron Pharmaceuticals: Regeneron markets EYLEA and EYLEA HD, the dominant anti-VEGF therapies for wet AMD, DME, and RVO that Eyconis aims to disrupt. Several Eyconis executives (Vitti, Chu, Drosman) led EYLEA development at Regeneron, making it the most relevant incumbent comparator in retinal disease.
• Roche/Genentech: Roche/Genentech markets Vabysmo (faricimab) and Lucentis, the principal dual-pathway/biologic competitors in wet AMD and DME. Eyconis COO Oliver Stauch led Lucentis and Vabysmo delivery innovation at Roche, making this the second key incumbent benchmark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eyconis-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyconis